Clinical Trial Update: Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial of polyunsaturated fatty acids as adjunctive treatment for refractory epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Polyunsaturated fatty acids (PUFA)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Epilepsy | Phase 3 | Status: COMPLETED